Kymera Therapeutics's total assets for Q2 2025 were $1.13B, an increase of 23.17% from the previous quarter. KYMR total liabilities were $159.59M for the fiscal quarter, a 20.83% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.